m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00623)
Name
AK-602
Synonyms
Trastuzumab emtansine; GW-873140; SCHEMBL20530710
    Click to Show/Hide
Status
Phase 3
Structure
Formula
C25H21N7O4
InChI
1S/C25H21N7O4/c1-14-8-21(30-36-14)23-28-27-22-19-4-2-3-5-20(19)24(29-32(22)23)35-12-16-7-6-15(10-26-16)25(33)31-11-18-9-17(31)13-34-18/h2-8,10,17-18H,9,11-13H2,1H3
InChIKey
WISMPDBQEVMXPG-UHFFFAOYSA-N
PubChem CID
135353969
INTEDE Drug ID
DR1629
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aldo-keto reductase 1C1 (AKR1C1)
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for AK-602. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AK-602 through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). [1], [2]
References
Ref 1 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.
Ref 2 The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7. doi: 10.1016/j.cbi.2014.07.005. Epub 2014 Jul 22.